Winship Cancer Institute

Emory University

Atlanta, GA

Sorting 23 by

Accepting patients

CARTITUDE-2

Phase 2, Open-Label Study Evaluating the Use of an Investigational CAR-T Cell therapy in Participants with Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • Phase 2

Accepting patients

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • GPRC5D
  • Phase 2

Accepting patients

MagnetisMM-7

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab VS Lenalidomide in Participants with Newly Diagnosed Multiple Myeloma Who Have Had an Autologous Stem Cell Transplant
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Phase 3

Accepting patients

MagnetisMM-20

Phase 1B Study Evaluating Elranatamab in Combination with Carfilzomib/Dexamethasone or in Combination with PF-07901801 (maplirpacept) in Relapsed/Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 1

Accepting patients

SUCCESSOR-2

Phase 3 Study Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Learn more
  • CELMoD
  • Randomization
  • Phase 3

Accepting patients

EXCALIBER RRMM

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Iberdomide, Daratumumab and Dexamethasone VS Daratumumab, Bortezomib, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Learn more
  • CELMoD
  • Randomization
  • Phase 3

Accepting patients

EXCALIBER-Maintenance

Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma
Learn more
  • CELMoD
  • Post-Autologous Stem Cell Transplant
  • Randomization
  • Phase 3

Accepting patients

KarMMa-2

Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • High Risk
  • Phase 2
  • Has results

Accepting patients

MonumenTAL-1

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Phase 2

Accepting patients

Personalized Autologous Transplant

Personalized Autologous Transplant for Multiple Myeloma
Learn more
  • Autologous Stem Cell Transplant
  • Vaccine
  • Phase 1
6 hidden based on your filters. Show All